209 filings
Page 5 of 11
8-K
supkufqwe jl5
12 Nov 20
Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
4:28pm
8-K
q77lh3equ0x mzeme
22 Oct 20
Regulation FD Disclosure
1:14pm
8-K
cdry1u
30 Sep 20
Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies
8:05am
8-K
yzpbrdlvzjbd4p 6xv
26 Aug 20
Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock
4:10pm
424B5
0u83ju j8xm96c26u834
26 Aug 20
Prospectus supplement for primary offering
4:07pm
8-K
dojw1vvj0of 7h
25 Aug 20
Other Events
7:00am
8-K
8s02w1g xg9v
10 Aug 20
Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
8:06am
8-K
08hg94z
13 Jul 20
Entry into a Material Definitive Agreement
7:06am
8-K
x3aqmvj jczvvelz
19 Jun 20
Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome
8:06am
8-K
ek3n qb3k1sos5tx
17 Jun 20
Regulation FD Disclosure
1:11pm
8-K
s6xyquvn74ld
5 Jun 20
Submission of Matters to a Vote of Security Holders
5:10pm
8-K
toruzo9
7 May 20
Ovid Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
8:10am
DEFA14A
4a9foeo wjs8ttks
24 Apr 20
Additional proxy soliciting materials
12:00am
8-K
i1jlg9iqqkzbp5slr
30 Mar 20
Ovid Therapeutics Announces Initial Data with Soticlestat in CDKL5 Deficiency Disorder and Dup15q Syndrome
8:05am
8-K
44lajrcu5edvb5b7qfd
13 Mar 20
Regulation FD Disclosure
9:06am